CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 13, 2005
Result type: Reports
Project Number: S0045
Product Line: Common Drug Review

Generic Name: Omalizumab

Brand Name: Xolair

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Asthma, severe persistent

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: March 7, 2006

Recommendation Type: Do not list